Preoperative measurement of serum CA-125 levels: is it useful in the risk assessment of low volume lymph node disease in cervical cancer?

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. DOI: 10.1016/S1470-2045(12)70211-510.1016/S1470-2045(12)70211-5Search in Google Scholar

2. Reports based on the data the Oncology Centre: http://85.128.14.124/krn/, www.onkologia.org. Access: 10.12.2017 05.04.2017.10.1055/s-0043-100246Search in Google Scholar

3. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol. 2007 Mar;104(3):508-15. DOI: 10.1016/j.ygyno. 2006.09.028Search in Google Scholar

4. Scharl A, Crombach G, Vierbuchen M, Müsch H, Bolte A. CA 125 in normal tissues and carcinomas of the uterine cervix, endometrium and fallopian tube. I. Immunohistochemical detection. Arch Gynecol Obstet. 1989 Jun;244(2):103-12. DOI: 10.1007/BF0093138110.1007/BF00931381Search in Google Scholar

5. Sadowski EA, Robbins JB, Guite K, Patel-Lippmann K, Del Rio AM, Kushner DM, et al. Preoperative pelvic MRI and serum cancer antigen-125: selecting women with grade 1 endometrial cancer for lymphadenectomy. AJR Am J Roentgenol. 2015 Nov;205(5):W556-64. DOI: 10.2214/AJR.14.1374610.2214/AJR.14.13746Search in Google Scholar

6. Rizzuto I, Stavraka C, Chatteriee J, Borley J, Hopkins TG, Gabra H, et al. Risk of Ovarian Cancer Relapse Score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. Int J Gynecol Cancer. 2015 Mar;25(3):416-22. DOI: 10.1097/IGC.000000000000036110.1097/IGC.0000000000000361Search in Google Scholar

7. Tsai CC, Liu YS, Huang EY, Huang SC, Chang HW, Tseng CW, ChangChien CC et al. Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol. 2006 Mar;100(3):591-5. DOI: 10.1016/j.ygyno.2005.09.04910.1016/j.ygyno.2005.09.049Search in Google Scholar

8. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20. DOI: 10.1016/j. critrevonc.2007.09.002Search in Google Scholar

9. Porika M, Vemunoori AK, Tippani R, Mohammad A, Bollam SR, Abbagani S. Squamous cell carcinoma antigen and cancer antigen 125 in southern Indian cervical cancer patients. Asian Pac J Cancer Prev. 2010 Jun;11(6):1745-7.Search in Google Scholar

10. Takeda M, Sakuragi N, Okamoto K, Todo Y, Minobe S, Nomura E, et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand. 2002 May;81(5):451-7. DOI: 10.1034/j.1600-0412.2002.810513.x10.1034/j.1600-0412.2002.810513.xSearch in Google Scholar

11. Koper NP, Thomas CM, Dorn KE, Schijf CP. Improvement of clinical staging in cervical cancer with serum squamous cell carcinoma antigen and CA 125 determinations. Gynecol Oncol. 1997 Mar;64(3):473-6. DOI: 10.1006/gyno.1996.458110.1006/gyno.1996.4581Search in Google Scholar

12. Avall-Lundqvist EH, Sjövall K, Nilsson BR, Eneroth PH. Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. Eur J Cancer. 1992;28A(10):1695-702. DOI: 10.1016/0959-8049(92)90071-910.1016/0959-8049(92)90071-9Search in Google Scholar

13. Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RH, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumour Biol. 2008;29(1):9-17. DOI: 10.1159/00013256610.1159/00013256618497544Search in Google Scholar

14. Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshiho K, Fujita M, et al. Serum biomarkers for early detection of gynecologic cancers. Cancers (Basel). 2010 Jun 14;2(2):1312-27. DOI: 10.3390/cancers202131210.3390/cancers2021312383513124281117Search in Google Scholar

15. Bats A, Mathevet P, Buenerd A, Orliaquet I, Mery E, Zerdoud S, et al. The sentinel node technique detects unexpected drainage pathways and allows nodal ultrastaging in early cervical cancer: insights from the multicenter prospective SENTICOL study. Ann Surg Oncol. 2013 Feb;20(2):413-22. DOI: 10.1245/s10434-012-2597-710.1245/s10434-012-2597-722911367Search in Google Scholar

16. Borras G, Molina R, Xercevanis J, Ballesta A, Iglesias J. Tumor antigens CA 19.9, CA 125, and CEA in carcinoma of the uterine cervix. Gynecol Oncol. 1995 May;57(2):205-11. DOI: 10.1006/gyno.1995.112610.1006/gyno.1995.11267729735Search in Google Scholar

17. Kotowicz B, Kaminska J, Fuksiewicz M, Kowalska M, Jonska-Gmyrek J, Gawrychowski K, et al. Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. Int J Gynecol Cancer. 2010 May;20(4):588-92. DOI: 10.1111/IGC.0b013e3181d5c27a10.1111/IGC.0b013e3181d5c27a20686378Search in Google Scholar

18. Yamazaki H, Todo Y, Okamoto K, Yamashiro K, Kato H. Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer. J Gynecol Oncol. 2015 Oct;26(4):255-61. DOI: 10.3802/jgo.2015.26.4.25510.3802/jgo.2015.26.4.255462036126197769Search in Google Scholar

19. Darai E, Rouzier R, Ballester M, Barranger E, Coutant C. Sentinel lymph node biopsy in gynaecological cancers: the importance of micrometastases in cervical cancer. Surg Oncol. 2008 Sep;17(3):227-35. DOI: 10.1016/j.suronc.2008.04.00210.1016/j.suronc.2008.04.00218504122Search in Google Scholar

20. Slama J, Dundr P, Dusek L, Fischerova D, Pinakavova I, Vrzackova P, et al. Sentinel lymph node status in patients with locally advanced cervical cancers and impact on neoadjuvant chemotherapy. Gynecol Oncol. 2012 May;125(2):303-6. DOI: 10.1016/j.ygyno.2012.02.01010.1016/j.ygyno.2012.02.01022342976Search in Google Scholar

21. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-4. DOI: 10.1016/j. ijgo.2009.02.009 DOI: 10.1016/j.ijgo.2009.02.012 Search in Google Scholar

22. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. April 15-22, 2001. Philadelphia. Pennsylvania. Cancer. 2002 May 15;94(10):2542-51. DOI: 10.1002/cncr.1053910.1002/cncr.1053912173319Search in Google Scholar

23. Singletary SE, Greene FL. Revision of breast cancer staging: the 6th edition of the TNM Classification. Semin Surg Oncol. 2003 Nov;21(1):53-9. DOI: 10.1002/ssu.1002110.1002/ssu.1002112923916Search in Google Scholar

24. Goldberg GL, Sklar A, O’Hanlan KA, Levine PA, Runowicz CD. CA-125: a potential prognostic indicator in patients with cervical cancer? Gynecol Oncol. 1991 Mar;40(3):222-4. DOI: 10.1016/0090-8258(90)90281- OSearch in Google Scholar

25. Divine LM, Kizer NT, Hagemann AR, Pittman ME, Chen L, Powell MA, et al. Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. Gynecol Oncol. 2016 Jul;142(1):76-82. DOI: 10.1016/j.ygyno.2016.04.03010.1016/j.ygyno.2016.04.030509638827117923Search in Google Scholar

26. Dasari S, Wudayagiri R, Valluru L. Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim Acta. 2015 May 20;445:7-11. DOI: 10.1016/j. cca.2015.03.005Search in Google Scholar

27. Rimel BJ, Burke WM, Higgins RV, Lee PS, Lutman CV, Parker L. Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice. Gynecol Oncol. 2015 May;137(2):280-4. DOI: 10.1016/j.ygyno. 2015.02.021Search in Google Scholar

28. Hoogendam JP, Zaal A, Rutten EG, Heijnen CJ, Kenter GG, Veldhuis WB, et al. Detection of cervical cancer recurrence during follow-up: a multivariable comparison of 9 frequently investigated serum biomarkers. Gynecol Oncol. 2013 Dec;131(3):655-60. DOI: 10.1016/j.ygyno.2013.10.01610.1016/j.ygyno.2013.10.01624157617Search in Google Scholar

29. Kupets R, Giede KC, Power P, Agrawal A; Executive of the Society Gynecologic Oncology of Canada. The investigations required before referring a patient to a gynecologic oncologist. J Obstet Gynaecol Can. 2016 Feb;38(2):164-7. DOI: 10.1016/j.jogc.2015.12.01610.1016/j.jogc.2015.12.01627032742Search in Google Scholar

30. Togami S, Sasajima Y, Kasamatsu T, Oda-Otomo R, Okada S, Ishikawa M, et al. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix. Pathol Oncol Res. 2015 Apr;21(2):487-94. DOI: 10.1007/s12253-014-9854-y 10.1007/s12253-014-9854-y25370301Search in Google Scholar